Patients must be encouraged to 'Talk Hypos'. (January 2015)

• Record Type: Journal Article
• Authors: Jensen, Klaus H
• Is Part Of: Diabetes management. Volume 5:Number 1(2015)
• Page Start: 13
• Page End: 15
• Publication Date: 2015-01
• Subjects: Changing Diabetes -- complications -- diabetes -- Hypo Awareness Week -- hypoglycemia -- Novo Nordisk -- patients -- Talk Hypos; Diabetes -- Periodicals; 616.462005
• DOI: 10.2217/dmt.14.56
• Languages: English
• ISSNs: 1758-1915

Abstract

Klaus Jensen* speaks to Daphne Boulicault, Commissioning Editor: A Copenhagen native, Klaus Henning Jensen started his career working as a medical doctor in a hospital setting. An entrepreneur at heart, he drew from his background in physics and business administration to co-found a device company – successfully developing a new type of surgical screw for osteosynthesis of hip fractures. Klaus' career at Novo Nordisk spans almost a decade and is rooted in Global Medical Affairs. He has held a series of Medical Director and Vice President roles with responsibilities cutting across the entire Novo Nordisk (UK and Ireland) diabetes portfolio – medical devices, Victoza ® (liraglutide), Tresiba ® (insulin degludec), Ryzodeg ® (insulin degludec/insulin aspart) and Xultophy ® (insulin degludec/liraglutide), as well as other GLP-1 and insulin treatments – with medical and scientific responsibility for the R&D of several of these products. He now sits on the UK & Ireland leadership team as Head of Clinical, Medical and Regulatory.